Kyverna Therapeutics, Inc. (KYTX) saw a 27.45% surge in its stock price, reaching $11.19, following positive clinical data for its CAR-T cell therapy program in autoimmune disease. The study met key objectives, showing promising efficacy signals and a safety profile consistent with expectations for CAR-T therapies. Kyverna plans to advance the program into later-stage development, with the stock trading in a range of $6.90 – $14.80. Investor confidence in Kyverna’s pipeline and the potential for CAR-T therapies in autoimmune diseases drove the sharp increase in stock price.

Read more at Nasdaq MarketSite: Kyverna Shares Jump 27% After Positive Topline Data From CAR-T Autoimmune Study